Digest Network Come funziona
Network
/
Società
iE
Non verificato

iECURE, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieSaluteScienza

13 comunicati stampa

Guarda tutti i comunicati
27/08/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
20/08/2026
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Assistenza all'Infanzia
Vetrine/Shopping
Medicina - Varie
iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
13/05/2026
Eventi
Fiere
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
28/04/2026
Telefonia e Varie
Fiere
Industria
Scienza
Infanzia
Assistenza all'Infanzia
Biotecnologia
Medicina - Varie
Salute
Vetrine/Shopping
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
18/03/2026
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Industria
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Igiene alimentare
Biotecnologia
Salute
Medicina - Varie
Industria
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Salute
Biotecnologia
Medicina - Varie
Scienza
Eventi
iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
25/08/2025
Scienza
Biotecnologia
Salute
Assistenza all'Infanzia
Vetrine/Shopping
Medicina - Varie
Eventi
Industria
iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Eventi
Salute
Vetrine/Shopping
Biotecnologia
Assistenza all'Infanzia
Medicina - Varie
Scienza
iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings
Fonte
iECURE, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0